Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2015
- Source ID
- 10.1016/j.jalz.2015.04.005
Entities
People
- Andrew J. Saykin
- Arthur W. Toga
- Clifford Jack
- Dallas P. Veitch
- Danielle Harvey
- Jesse Cedarbaum
- John C. Morris
- John Q. Trojanowski
- Laurel A. Beckett
- Leslie M. Shaw
- Michael C. Donohue
- Michael W. Weiner
- Nigel J. Cairns
- Paul M. Thompson
- Paul S. Aisen
- Robert C. Green
- Ronald C. Petersen
- The Alzheimer’s Disease Neuroimaging Initiative*
- William J. Jagust
Organizations
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- AstraZeneca
- Avid Radiopharmaceuticals
- Bayer HealthCare
- BioClinica
- Biogen
- Bristol-Myers Squibb
- California Breast Cancer Research Program
- Cure Alzheimer's Fund
- Eisai
- GE HealthCare
- GSK
- Harvard Medical School
- Helen Wills Neuroscience Institute
- Hoffmann-La Roche
- Indiana University
- Innogenetics
- Loma Linda University Medical Center
- Mayo Clinic
- Medpace
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Mental Health
- National Institute of Neurological Disorders and Stroke
- National Institute on Aging
- National Institutes of Health
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- United States National Library of Medicine
- University of California, Davis
- University of California, San Diego
- University of California, San Francisco
- University of Pennsylvania
- University of Southern California
- Washington University in St. Louis
- Wyeth